A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.
A clinical trial tests the diabetes drug metformin and transplant rejection preventative rapamycin to act as maintenance chemotherapy for pancreatic cancer.